VYNE Therapeutics FY 2021: revenue $14.8M, down 30%; diluted EPS $25.54

Key figures from this report

These are the numbers VYNE Therapeutics reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$14.8M−30% from $21.0M in FY 202010-K income statement, on EDGAR
2. Net income−$73.3MAgainst −$255.6M in FY 202010-K income statement, on EDGAR
3. Diluted EPS$25.54−82% from $141.73 in FY 2020. Split-adjusted, as the tables show it; the filing reported $1.4210-K income statement, on EDGAR
4. Cash and cash equivalents$42.3M−27% from $57.6M in FY 2020Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations−$56.4MAgainst −$137.1M in FY 202010-K cash flow statement, on EDGAR

Every year in the financial tables